TREATMENT OF PIGMENT EPITHELIAL DETACHMENT USING BEVACIZUMAB

Background: Pigment epithelial detachment (PED) is a pathological process in which the retinal
pigment epithelium separates from its underlying membrane (Bruch). Although the PED can be
spread in macular disorders, coherence of disorder with degenerative age-related macular
neovascularization is impressive and can be marker of disease, disease progression and in some
cases the indicator as resistance to treatment.
Objective: The aim of this study was to evaluate the effect of bevacizumab in the treatment of
pigment epithelial detachment.
Methods: In this retrospective study the data of patients with detachment of pigment epithelial were
studied who referred to eye clinic in Imam Khomeini hospital of Urmia, Iran and treated by
bevacizumab. Variables of study included age, sex, height of PED before injection of bevacizumab
and 1, 3, 6 and 12 months after injection of bevacizumab. Under sterile Conditions and after
prepping and draping and setting speculum in aphakic and pseudophakic patients, injection from
distance of 3.5mm of limbus and in phakic patients from distance of 4mm of limbus administrated
with dosage of 1.25 mg bevacizumab.5 days after surgery, eye drop betamethasone every 4hours
and tablet of ciprofloxacin 500 mg every 12 hours were administered.
Results: In this retrospective study, 30 patients with pigment epithelium detachment who have been
treated by bevacizumab were studied. Age range was from 58 to 79 years and the average age of the
patients was 70.16±5.99 years. In this study 16 patients were female (53.3%) and 14 patients were
male (46.7%).The average height of PED before injection was compared to the average height of
PED 1, 3, 4 and 12 months after injection and it was significantly different (P=0.001)
Conclusion: Bevacizumab can be an appropriate treatment for patients with pigment epithelium
detachment.
Funding: This research has been financially supported by Research Council of Mashhad University
of Medical Sciences.